Waystar Considers Sale of Healthcare Payments Software Firm

Healthcare payments software firm Waystar is reportedly exploring the possibility of selling the company, according to a Reuters report published on Tuesday, September 15. The news source cited seven sources familiar with the matter, stating that the business has engaged bankers to advise on a potential sale. However, the report emphasized that the plans are not set in stone and may not materialize.

PYMNTS reached out to Waystar for a comment, but as of yet, no response has been received. The article highlighted that Waystar's objective was to position itself as a healthcare software company, offering technology to streamline and manage administrative tasks, rather than as a healthcare services business reliant on human personnel.

This approach was intended to secure higher valuations typically associated with technology companies when Waystar went public in 2024. Initial investor enthusiasm was evident, but the company's stock experienced a decline due to apprehensions regarding potential disruption from artificial intelligence (AI). Morgan Stanley's report on AI vulnerabilities in software firms was referenced by Reuters.

Furthermore, PYMNTS published two recent articles on September 15 that underscore the significance of the healthcare sector as a valuable testing ground for the future of B2B payments. The article highlighted Forus, an AI network for medicine, which recently secured $150 million in Series C financing at a $3 billion valuation. Verily Health, another company, announced a new investment from Nvidia and additional funding from existing investors on September 9, aimed at assisting healthcare organizations in preparing their data for AI integration and responsible deployment of artificial intelligence.